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Introduction
Genotoxins are chemicals that induce DNA mutations that can lead to cancer. Mutation in genes essential to perform normal regulatory processes like controlled cell signalling, cell cycle checkpoints and apoptosis, can lead to cancer development [1] . Some genotoxic chemicals, when released into the environment, can remain intact for long periods of time and cause adverse effects. It is important to assess the genotoxic potential of such chemicals for a better understanding of their carcinogenicity in order to reduce the potential risk of human cancer and other diseases involving acquired mutations in the somatic cells.
The link between environmental chemical exposure and human disease was first recorded in 1775 with the discovery of chimney sweeper's cancer (soot wart), a squamous cell carcinoma of the skin of the scrotum, which originated from the components of soot [2] . The first report of the induction of squamous cell papilloma on rabbit ears after repeated exposure of coal tar, was published in 1918 [3] . Kennaway, in 1930 , found that tumours in mouse skin could be produced by pure 1, 2, 5, 6 dibenzanthracene [4] . Later on in 1932, Cook and colleagues successfully isolated polycyclic aromatic hydrocarbon, benzo[a]pyrene (PAH, B[a]P) from coal tar, a highly carcinogenic crystalline compound [5] .
B[a]P belongs to a family of chemicals that can act like dioxins, based on a common mechanism of toxic action. Like dioxin compounds, PAHs have biologic responses mediated via binding to the aryl hydrocarbon receptor (AhR) which is a specific high-affinity cellular reporter protein [6] despite PAHs being quite different structurally from dioxins. Due to their potential risk to humans and animals, the United States Environmental Protection Agency (US-EPA) has designated 126 PAHs as priorities for environmental concern and B[a]P is one which is frequently monitored in the environment. B[a]P is generated through the burning of fossils fuels or wood, vehicle exhaust emission, heat and power generation, industrial processes or oil contamination and is always found environmentally as a mixture with other PAHs as in cigarette smoke, charcoal-cooked food and industrial waste by-products [7, 8] .
Human environmental exposure to B[a]P mainly occurs through cigarette smoking and the ingestion of contaminated food and water [7] , with significant concentrations found in Western diet such as in fried and grilled meats. Both environmental and dietary factors are associated with an increased risk of different organ cancers [9] , autoimmune [10] and inflammatory diseases [11] . The daily intake of B[a]P in the average human diet has been estimated to range from 120-2800ng/day [12] and concentration of B[a]P in full flavoured cigarettes has also been reported to be about 10ng per cigarette [13, 14] , which is equivalent to an intake of about 200ng/day for a pack-a-day cigarette smoker [15] . B[a]P is transported across the cell membrane by lipoproteins [16] [17] . BPDE contains an epoxide ring within the bay region making it highly reactive with DNA in a time dependent manner.
The genotoxicity of most direct acting genotoxins is dependent on the dose and length of exposure whereby genotoxic effects are observed at or above a critical dose. These doses are referred to as threshold doses, below which no observable genotoxic effect is seen. Nowadays a threshold level is commonly used to determine or establish a safe limit of a chemical for human use but only when their mechanism of action is established and accepted by risk assessment agencies. This threshold limit is derived from a combination of dose-dependent responses, mathematical and statistical models, to cover any variability, and risk assessment procedures. Typically a threshold level is a value between a no observable effect level (NOEL) and lowest observable effect level (LOEL) [18] and can be confirmed by mathematical modelling [19] . The nature of the chemical, its interaction with the non-DNA targets, and cell protective mechanisms (detoxification, DNA repair, etc.) are the mechanistic factors that influence dose-dependent responses [19] . Therefore, it is important to consider these factors while assessing if thresholds exist for any genotoxins. These considerations become even more complex if the genotoxin involved is a pro-carcinogen that requires metabolic activation to initiate genotoxicity. As compared to direct acting agents, little is known about the threshold doses of pro-carcinogenic agents and the critical factors controlling dose response relationships for genotoxicity.
Considering this, the aim of this study was to identify the dose responses at the low dose range of B[a]P and determine whether there is differential genotoxicity and mutagenicity of B[a]P in different human cell lines based on their metabolic capacity of phase I enzymes. The cell lines used in the present study were human lymphoblastoid cell lines AHH-1, MCL-5, TK6 and primary hepatoblastoma cell line HepG2, known to have differential expression of phase I CYP450 enzymes. AHH-1 cell line only expresses CYP1A1, MCL-5 cells express all five CYP450 enzymes (detailed information for each cell line in Material and Method section). TK6 cells were used as a control as they are devoid of CYP450 enzymes. Therefore, all of these cell lines serve as a good tool to investigate the role of P450 enzymes in assessing the genotoxicity of chemicals that require metabolic activation. The stable expression system also furthers understanding of the process from metabolic activation of test compounds to the appearance of toxicological consequences entirely in the same intact cells.
The study utilised the in vitro cytokinesis blocked micronucleus (CBMN) assay and hypoxanthine (guanine) phosphoribosyltransferase (H(G)PRT) assay in human cell lines to examine the induction of chromosomal damage and the frequency and spectra of point mutations, respectively. CYP450 enzymes levels and activity were also investigated in parallel through gene expression analysis and reporter assays. were purchased from Sigma (Gillingham, UK). N-Cyclohexyl-N-dodecylurea (NCND) was purchased from Calbiochem (EMD Chemicals Inc. US). Cytochalasin B was from Merck (Darmstadt, Germany). All powdered reagents were reconstituted according to manufacturer's instructions. All chemical dilutions were freshly prepared from stock solutions and for each experiment new stock was prepared.
Materials and Methods

Reagents
Cell Culture
The present study utilised human male lymphoblastoid cell lines AHH-1, MCL-5 (ATCC, Middlesex, UK), TK6 and human hepatoma cell line HepG2 (ECACC, Salisbury, UK). The cell cycle doubling time for TK6 was 18h, for AHH-1 and MCL-5 22-24h, and 26-28h for HepG2. TK6 was isolated from WIL2, heterozygous at thymidine kinase (TK) locus and has a stable and wild-type p53 gene but minimal or no expression of CYP450 enzymes.
AHH-1 is a TK+/-with native CYP1A1 activity which was used for oxidative xenobiotic metabolism and was devoid of microsomal epoxide hydrolase [20] . It has +/-p53 gene.
MCL-5 cell line was a derivative of AHH-1 TK+/-that has been transfected with 4 cDNAs of the human CYP450s (carried on plasmids). These cDNAs include CYPA12, CYP2A6, CYP3A4 and CYP2E1 and microsomal epoxide hydrolase (mEH). MCL-5 has been shown to be more sensitive than AHH-1 TK+/-to the mutagenic properties of many pro-mutagens and pro-carcinogens and direct acting agents [21] . The plasmids were maintained in these cells through hygromycin (B) resistant genes. Both AHH-1 and MCL-5 harbour a heterozygous transition (C>T) p53 mutation at the codon 281/282 interface within exon 8, it retains the ability to undergo DNA damage-induced apoptosis and has been reported to express p53 which can be phosphorylated [22] .
HepG2 cells were isolated by Aden et al, (1997) from a primary hepatoblastome of an 11-year-old Argentine boy [23] . HepG2 have epithelial like morphology which resembles liver parenchymal cells and retain many of the specialized functions in culture such as secretion of major plasma proteins [24] . This cell line is a useful model of human liver cells and expresses many functional phase I and phase II xenobiotic metabolic enzymes [25] .
All media used were purchased from GIBCO® (Life technologies, Paisley, UK) unless otherwise stated.
The cell lines AHH-1, MCL-5, and TK6 were cultured in RPMI 1640 supplemented with 1% L-glutamine and 10% donor horse serum (BD Gentest, Oxford, UK) in 80-cm 2 flasks at 37°C, 5% CO 2 . In addition, MCL-5 cells were supplemented with hygromycin B at each passage to ensure plasmid retention. The cells were maintained at a concentration of 1-2 x 10 5 cells/ml. HepG2 cell line was cultured in DMEM, supplemented with 10% foetal bovine serum and Pen/strep (penicilin and streptomycin [10,000U/ml]) and maintained at a concentration of 1.5-2 x 10 5 cells/cm 2 . Each experiment was repeated three times and each replicate was independently produced on different days. The highest concentration of B[a]P used here caused a maximum of 40+/-5% toxicity as adjusted by plating efficiency (PE). This is within the acceptable range for testing as described in the OECD guidelines 476 [27] .
Treatment with B[a]P
For the measurement of CYP1A1, CYP1B1, and CYP1A2 expressions and activities all cell lines were treated with LOELconcentration and concentration above LOEL of B[a]P for 24h, obtained as a result of CBMN assay.
All the washing steps involved were done at room temperature and all centrifugation steps performed at (300 x g) for 5min.
Cytotoxicity assessment using relative population doubling
The cytotoxicity of B[a]P dissolved in DMSO was determined by relative population doubling (RPD) in the absence of cytochalasin B following the procedure described by Brüsehafer et al. [28] with a few modifications. HepG2 cells were seeded at 1.2x10 5 cells/cm 2 at 37ºC, 5% CO 2 , cells from each treatment flask were counted (control treatment) with the Beckman coulter counter (Z1 Coulter Particle Counter, Beckman, UK) and incubated for 24h. AHH-1, MCL-5 and TK6 cells were seeded at 1x10 5 cells/ml for 24h and cells were counted (control treatment) from each flask 1h before treatment. All four cell lines were again counted at the cell harvest stage (treated cultures).
The Cytokinesis blocked micronucleus assay
Micronuclei (MN) frequency was utilized to assess the in vitro level of chromosomal damage induction.
The assay was performed as previously described by Seager et al. [29] with a few modifications. AHH-1, MCL-5 and TK6 (10ml) suspensions of cells at 1 x 10 5 cells/ml and HepG2 at 1.2 x 10 5 cells/cm 2 , were seeded for 24h at 37°C, 5% CO 2 . Flasks were treated with appropriately diluted B[a]P for 4h or 24h, after which AHH-1, MCL-5 and TK6 cells were centrifuged (pipetted off the medium from HepG2 flasks), washed twice with RPMI 1640 (without supplement), and re-suspended in 10ml fresh media containing 6µg/ml cytochalasin B for one cell cycle (22h for AHH-1 and MCL-5 and 26h for HepG2), 3µg/ml for TK6 (18h). Treated cells (AHH-1, MCL-5 and TK6) were washed twice by centrifugation with PBS while HepG2 cells were washed twice and then trypsinised. Slides were prepared for the Metafer 4 software, version 3.8.5 (MetaSystems, Altlussheim, Germany) as described by Seager et al. [30] . A minimum of 3333 binucleated cells were scored per replicate, and each treatment was performed in triplicate (an average of 10,000 binucleates per treatment).
The hypoxanthine phosphoribosyltransferase assay
The in vitro HPRT assay was used to study the gene mutations at HPRT locus.To reduce the background mutants, AHH-1 and MCL-5 cells were cultured for 3 days in RPMI 1640 containing 50X HAT media, which is lethal to cells that harbour mutations at the HPRT. Subsequently, the cells were transferred to media containing 50X HT media for 24h and then grown in normal media for two days to achieve sufficient cell number for treatments.
The assay was performed as previously described by Doak et al. [31] , with the following modifications:
AHH-1and MCL-5 cell suspensions (10 ml), at 4 x 10 5 cells/ml, were exposed to the test chemical in 80-cm 3 flasks at the appropriate concentration for 4h or 24h at 37°C, 5% CO 2 . It was noted by using the two-tailed ttest that the mutant frequency (MF) of the solvent control (DMSO) is non-significantly different from that of the untreated control, with MF being 0.18×10 −5 ± 0.03 (mean ± SE) and 0.26×10 −5 ± 0.03, respectively for AHH-1 and 2.2×10 −5 ± 0.15 (mean ± SE) and 2.39×10 −5 ± 0.13, respectively for MCL-5. College, PA). Any mutation found was confirmed by repeat processing.
Clonal expansion of mutants
Construction of mutation spectra
Mutation spectra were constructed using iMARS sofware [33] .
Expression of CYP450 enzymes using quantitative real-time PCR
The expression of CYP1A1, CYP1B1, and CYP1A2 mRNA in human cell lines AHH-1, MCL-5, TK6
and HepG2 was evaluated qualitatively using real-time reverse transcriptase-PCR. MCL-5, AHH-1 and TK6 cells were seeded at a density of 1x10 5 cells/ml and HepG2 at 1.2x10 5 cells/cm 2 . After 24h incubation cells were exposed for 24h with B[a]P. Following the exposure period cells were washed twice and the RNA was extracted as mentioned previously. The purified RNA samples were reverse transcribed using the QuantiTect ® Reverse Transcription Kit from Qiagen (Sussex, UK) according to manufacturer's instructions. All the primers were synthesized by Sigma-Aldrich (UK) and the oligonucleotide sequence and product size for each primer were as follows;
and CYP1B1-forward,5ʹ-TCCTCCTCTTCACCAGGTATCC-3ʹ, reverse, 5ʹ-TGGTCACCCATACAAGGCAG-3ʹ with product size 97bp. Real-time PCR was then performed on an iCycler iQ5 Thermal Cycler (Bio-Rad, Hertfordshire, UK) using the QuantiFast SYBR Green PCR Kit (Qiagen). The resultant data were analysed by the standard curve method and genes of interest were normalized against β-actin.
Measurement of CYP450 activity
The CYP450 activity was determined using the P450-Glo 1A1 assay, 1B1 assay and 1A2 assay kits (Promega, USA), according to the manufacturer's instructions. MCL-5, AHH-1 and TK6 cells were seeded at a density of 1x10 5 cells/ml and HepG2 at 1.2x10 5 cells/cm 2 . After 24h incubation cells were exposed for 24h with activities were calculated by subtracting the background and normalizing to the seeded cell number.
Statistical analysis
For the cytotoxicity data error bars, are represented as standard errors (SEs) of the mean. For genotoxicity data a one-way ANOVA approach, followed by two-tailed Dunnett's post hoc test, was used to determine if any of the treatment doses were significantly different from the zero dose (p<0.05), except in the HPRT assay the control and solvent control were analysed using t-test. The hockey stick modelling of apparent thresholds was carried out using software, kindly provided by Lutz and Lutz [34] and implemented in the R package. A one-way ANOVA approach, followed by two-tailed Dunnett's post hoc test, was used to determine the basal and induced expression of CYP450 enzymes after B[a]P treatments.
Results
The present study explored the contribution of metabolic capacity on the genotoxic dose responses obtained for B[a]P. The cell lines selected to assess the induction of MN and HPRT mutations by B[a]P have varying metabolic competency.
The CBMN assay to determine B[a]P induced genotoxicity
The cell lines TK6, AHH-1, MCL-5 and HepG2 were tested for their ability to metabolise B[a]P into toxic/genotoxic metabolites after 24h exposure, as measured by cell viability and induced DNA damage. B[a]P did not show any significant cytotoxic or genotoxic effects in the TK6 cell line at any of the doses tested 1-70µM ( Figure 1A) . In contrast to TK6, AHH-1 cells showed a slight increase in cytotoxicity, (55+5% cytotoxicity was not achieved even at highest concentration of 70µM. However, a gradual increase in genotoxic 
Role of microsomal epoxide hydrolase in micronuclei induction
To confirm the importance of mEH in inducing an increased genotoxic potential and potency of B[a]P, as shown in MCL-5 cells specifically, N-Cyclohexyl-N'-dodecylurea (NCND), an effective inhibitor for mEH [37] was used. When MCL-5 cells were pre-treated for 2h with NCND (dose 170nM) and then exposed to 70µM B[a]P for 24h MN induction decreased (1.6-fold) and cytotoxicity reduced from 84% to 25% as compared to cells without pre-treatment.
Mutation frequency at HPRT loci for B[a]P
The HPRT assay was also performed in both AHH-1 and MCL-5 cells in order to study the mutagenic (less than that of the corresponding MN assay) ( Figure 4A ). MCL-5 was observed to be far more sensitive than AHH-1 in term of mutation induction. Hockey stick modelling revealed that B[a]P exhibited a linear doseresponse in both AHH-1 and MCL-5 cells after 24h exposure and no threshold dose was found.
There was a non-significant difference in % cell viability observed in both MCL-5 and AHH-1 cell lines when exposed to B[a]P for a shorter time of 4h. The MF was not increased in AHH-1 cells at all but it was significantly elevated with increasing concentration in MCL-5 cell line and the LOEL was found to be 10μM (p<0.01) with a linear dose response ( Figure 4B ), compared to a LOEL at 2µM with 24h exposure.
Spontaneous and B[a]P-induced Mutations in AHH-1 and MCL-5 HPRT mutants
A clear difference was seen in the patterns of the HPRT mutations from AHH-1 (Table I , Supplementary Table S1A ) and MCL-5 (Table I , Supplementary Table S1B ) solvent control and B[a]P treated mutants.
In the AHH-1 solvent control, a total of 14 spontaneous mutations were observed with deletions (93%)
being the most dominant mutations ( Figure 5A ). The remaining 7% of mutations represented a single tandem mutation (TG285/6AT) ( Supplementary Table S1A ). B[a]P treated AHH-1 mutants showed predominantly (61%) point mutations, out of which 44.4% were G>T transversions. Other mutations such as CT transitions (11%), insertions (5.5%), and deletions (33%) were also observed (Table I, Figure 5B ). There were no transitions or transversions mutations in AHH-1 control cells and the ratio of transitions;transversions was 2:9 in B[a]P-treated cells. In the MCL-5 solvent mutants, 25 mutations were analysed and the mutational spectrum constituted 40% deletions, 36% transversions and 12% transitions mutations and 12% TG285/6AT tandem mutations (same mutation as AHH-1) were also observed (Table I, Figure 5C ). B[a]P induced mutants predominantly contained point mutations (80%). Among all the point mutations, the proportion of G>T transversion mutations was higher (72% as compared to 4% transitions). The remaining 20% mutations detected were deletions (Table I, Figure 5D ). The transitions:transversions ratio in control cells Figure 6A ). The change in CYP1B1 expression, after 24h B[a]P exposure at the corresponding LOEL concentration was 10.52-fold (p<0.05) in MCL-5, but no effect was found in HepG2 ( Figure 6B) . B[a]P-induced CYP1A2 expression was elevated by 4.43-fold (p<0.001) and
18.95-fold (p<0.05) in the MCL-5 and HepG2 cell lines respectively ( Figure 6C ).
CYP activity in different cell lines
CYP1A1, 1B1 and 1A2 enzyme activities in MCL-5, AHH-1, TK6 and HepG2 cultures were also assessed after 24h B[a]P exposure (Figure 7) using enzyme activity assays. CYP1A1 activity was significantly higher in MCL-5 than other cell lines, reflecting the mRNA results above. CYP1A1 activity increased significantly (p<0.01) with increase in concentration of B[a]P in all cell lines except TK6 ( Figure 7A ).
CYP1B1 activity was significantly (p<0.05) high in both MCL-5 and HepG2 cells but was minimal in AHH-1 and TK6 ( Figure 7B ). CYP1A2 activity was highly significant (p<0.001) in HepG2 cells at all treatments, reflecting the mRNA data above, with MCL-5 cells also showing activity. AHH-1 and TK6 cell did not show an increase in CYP1A2 activity at any treatment ( Figure 7C ).
Discussion
This study assessed the interplay between treatment and metabolic competence in determining genotoxic hazard in vitro. This is an important aspect in both hazard identification and risk assessment for chemicals that require metabolic activation. In the former, the most sensitive test is usually used to increase the chances of detecting potential pro-mutagens, but in the latter, it is important to recognise the appropriateness of the system overall, to better reflect human risks.
Effect of differential metabolic competency on micronucleus frequencies after 4h and 24h exposure
The micronucleus assay data and gene expression and activity analysis of CYP1A1, CYP1B1 and which a significant increase in genotoxicity was first observed was much lower in MCL-5 and HepG2 cells than AHH-1 (Figure 1) . The results obtained with AHH-1 cells support the earlier studies of Penman et al. [20] who also observed that lower levels of CYP1A1 and an absence of mEH made the AHH-1 cell line less metabolicaly competent. The link between mEH and B[a]P metabolism was observed when MCL-5 cells treated with NCND (an effective inhibitor for mEH) [37] . These findings indicate that B[a]P conversion to its mutagenic intermediates in cells devoid of mEH and with lower CYP1A1 levels, is slow and thus requires more time to convert similar quantities of B[a]P into its genotoxic metabolites .
Dose response thresholds for genotoxins can be used to assist the prediction of a safe exposure level.
The theory behind genotoxic thresholds suggests that a compound will not produce an observable increase in DNA mutation below a critical exposure level and therefore, this does not increase the risk for the induction of cancer or congenital abnormalities. In this study, presence of a linear dose-response for MN at 24h exposure to B[a]P for all the metabolically competent cell lines may be explained by the potent formation of stable DNA adducts at N2-guanosine residues [42] which if left unrepaired, can block replication and transcription. Even a single BPDE-DNA adduct can effectively block expression of a reporter gene [43] and has been linked to mutations in multiple oncogenes including p53 and Kras, causing severe damage to cell integrity, function and replication [44] . It is important to note however, that this linearity is intrinsically linked to metabolic capacity.
It would be interesting to further study the dose responses to B[a]P in target tissues (e.g. lung) with intrinsic levels of metabolism likely to be far less than the MCL-5 and HepG2 cells here.
Comparison of the chromosome damage LOEL to the mutational LOEL
MCL-5 cells were more sensitive than AHH-1 cells to B[a]P-induced genotoxicity in general, which was likely due to the higher CYP450 enzyme expression in MCL-5 ( Figure 6 ). However, the lesions that cause gene mutations (HPRT here) may be different from those that cause chromosomal breaks (micronuclei).
Micronucleus formation occurs after multiple events including strand breaks during mitotic or failed DNA repair, whereas the HPRT assay can detect a single modification in the DNA mis-replicated during DNA synthesis. This increased assay sensitivity is reflected in the LOELs for HPRT mutations tending to be lower In conclusion, this study shows that TK6 cells have negligible metabolic ability to metabolise B[a]P, and showed no cyotoxicity nor genotoxicity, confirming that B[a]P is non-toxic without metabolic conversion.
We further show that CYP450 enzymes and mEH play an important role in the metabolic activation of B[a]P and the combined presence of CYP1A1, CYP1A2 and mEH caused MCL-5 and HepG2 cells to acquire more micronuclei and HPRT mutations compared to AHH-1 cells. The present study, thus emphasises the importance of considering the metabolic efficiency of in vitro cell systems when assessing dose responses to procarcinogens. We also suggest that metabolically competent cell lines offer an attractive alternative to rat liver S9 which may not necessarily be reflective of human liver physiology. 
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